Korro Bio, a biopharmaceutical company specializing in RNA editing-based genetic medicines, announced that its top executives will participate in two upcoming investor conferences in May 2026. The events include the HCW 4th Annual BioConnect Nasdaq Investor Conference on May 19 and the RBC Capital Markets Global Healthcare Conference on May 20. These presentations will highlight Korro's innovative OPERA platform, which enables precise RNA editing to develop treatments for rare and common diseases. This exposure aims to attract investor interest and provide updates on Korro's progress in advancing its genetic medicine pipeline.
LEPAS, a mid-to-premium NEV brand under Chery Auto, has introduced the LEPAS L8 PHEV globally, showcasing advanced hybrid technology, smart driving features, and refined design inspired by the agility and resilience of a leopard. The vehicle offers a...
LEPAS, a mid-to-premium NEV brand under Chery Auto, introduced the LEPAS L8 PHEV globally, featuring advanced hybrid technology, elegant design inspired by the agility and strength of a leopard, and smart driving aids. The vehicle offers a leading th...
Chery Auto's NEV brand LEPAS has introduced the LEPAS L8 PHEV globally, combining advanced hybrid technology with intelligent driving features and sophisticated design. Inspired by the precision and resilience of top athletes, the vehicle features a ...
LEPAS, a premium NEV brand under Chery Auto, has introduced the LEPAS L8 PHEV globally, blending elegant design inspired by a leopard's agility with advanced hybrid technology. The vehicle features a highly efficient LEPAS Super Hybrid system with a ...
Chery Auto's LEPAS brand has introduced the L8 PHEV, a mid-to-premium plug-in hybrid vehicle, to the global market. The car features advanced hybrid technology with a 45.79% efficient engine and a 97.6% efficient transmission, delivering ultra-low fu...
